Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:00 a.m. EST. CEO Richard Pops will lead the virtual session, which includes a question and answer segment. The presentation can be accessed under the Investors tab on Alkermes' website and will be archived for 14 days. Alkermes specializes in developing innovative medicines for neuroscience and oncology, with a focus on addiction and schizophrenia. The company is headquartered in Dublin, Ireland.

News Market Reaction – ALKS

+5.56%

+5.56% Session move

In the trading session that priced this news, ALKS gained 5.56%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Jan. 6, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 39^th Annual J.P. Morgan Healthcare Conference. The presentation will take place virtually on Wednesday, Jan. 13, 2021 at 10:00 a.m. EST (3:00 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Contact:
Alex Braun
Investor Relations
+1 781 296 8493

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301201851.html

SOURCE Alkermes plc

FAQ

When is Alkermes presenting at the J.P. Morgan Healthcare Conference?

Alkermes is presenting on January 13, 2021, at 10:00 a.m. EST.

Who is presenting for Alkermes at the conference?

CEO Richard Pops will provide the corporate overview.

How can I access Alkermes' presentation at the conference?

The presentation can be accessed under the Investors tab on Alkermes' website.

Will Alkermes' presentation be available after the live event?

Yes, the presentation will be archived for 14 days on their website.

What areas does Alkermes focus on in its drug development?

Alkermes develops innovative medicines in neuroscience and oncology, particularly for addiction and schizophrenia.